Development of a novel, fully-automated genotyping system: Principle and applications

Sensors (Switzerland)

Volumn 12, Issue 12, 2012, Pages 16614-16627

  Suzuki, Shun Ichi ^a   Komori, Mariko ^a   Hirai, Mitsuharu ^a   Ureshino, Norio ^b,c   Kimura, Shinya ^b  

^a ARKRAY Healthcare Pvt Ltd   (Japan)

^b SAGA UNIVERSITY   (Japan)

^c Saga Prefectural Hospital Koseikan   (Japan)

Author keywords

Automated genotyping system; I densy ; Mutation biased PCR; Personalized medicine; Pharmacogenetic analysis; Qprobe; Single nucleotide polymorphism

Indexed keywords

GENOTYPING; MUTATION BIASED PCR; PERSONALIZED MEDICINES; PHARMACOGENETIC ANALYSIS; QPROBE; SINGLE NUCLEOTIDE POLYMORPHISMS;

DRUG THERAPY; NUCLEOTIDES; OPTIMIZATION;

POLYMERASE CHAIN REACTION;

BILIRUBIN URIDINE DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; BILIRUBIN URIDINE-DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; CYP2C19 PROTEIN, HUMAN; DNA; GLUCURONOSYLTRANSFERASE; UNSPECIFIC MONOOXYGENASE;

BLOOD; GENETIC PROCEDURES; GENETIC SCREENING; GENETICS; GENOTYPING TECHNIQUE; HUMAN; METHODOLOGY; PHARMACOGENETICS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ARYL HYDROCARBON HYDROXYLASES; BIOSENSING TECHNIQUES; DNA; GENETIC TESTING; GENOTYPING TECHNIQUES; GLUCURONOSYLTRANSFERASE; HUMANS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84871692012     PISSN: 14248220     EISSN: None     Source Type: Journal    
DOI: 10.3390/s121216614     Document Type: Review

References (42)

1. Crews, K.R.; Gaedigk, A.; Dunnenberger, H.M.; Klein, T.E.; Shen, D.D.; Callaghan, J.T.; Kharasch, E.D.; Skaar, T.C. Clinical pharmacogenetics implementation consortium (cpic) guidelines for codeine therapy in the context of cytochrome p450 2d6 (cyp2d6) genotype. Clin. Pharm. Therapeut. 2012, 91, 321-326.
2. Flockhart, D.A.; Skaar, T.; Berlin, D.S.; Klein, T.E.; Nguyen, A.T. Clinically available pharmacogenomics tests. Clin. Pharm. Therapeut. 2009, 86, 109-113.
3. Dienstmann, R.; Martinez, P.; Felip, E. Personalizing therapy with targeted agents in non-small cell lung cancer. Oncotarget 2011, 2, 165-177.
4. Evans, W.E.; Relling, M.V. Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 1999, 286, 487-491.
5. Shah, R.R. Pharmacogenetics in drug regulation: Promise, potential and pitfalls. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2005, 360, 1617-1638.
6. Kennedy, M.J.; Phan, H.; Benavides, S.; Potts, A.; Sorensen, S. The role of the pediatric pharmacist in personalized medicine and clinical pharmacogenomics for children: Pediatric pharmacogenomics working group. J. Pediatr. Pharmacol. Ther. 2011, 16, 118-122.
7. Kurata, S.; Kanagawa, T.; Yamada, K.; Torimura, M.; Yokomaku, T.; Kamagata, Y.; Kurane, R. Fluorescent quenching-based quantitative detection of specific DNA/rna using a bodipy(r) fl-labeled probe or primer. Nucleic Acid. Res. 2001, 29, E34.
8. Ureshino, N.; Aragane, N.; Nakamura, T.; Ide, M.; Mochinaga, S.; Fukushima, N.; Hayashi, S.; Sueoka, E.; Kimura, S. A fully integrated and automated detection system for single nucleotide polymorphisms of ugt1a1 and cyp2c19. Oncol. Res. 2011, 19, 111-114.
9. Tanaka, R.; Kuroda, J.; Stevenson, W.; Ashihara, E.; Ishikawa, T.; Taki, T.; Kobayashi, Y.; Kamitsuji, Y.; Kawata, E.; Takeuchi, M.; et al. Fully automated and super-rapid system for the detection of jak2v617f mutation. Leuk. Res. 2008, 32, 1462-1467.
10. Mitsuharu, H.; Toshiya, H.; Aki, I. Method for Amplification of Target Nucleic Acid Sequence, Method for Detection of Mutation by Using the Method, and Reagents for Use in the Methods. WO/2010/001969, 7 January 2010.
11. Wakita, S.; Yamaguchi, H.; Miyake, K.; Mitamura, Y.; Kosaka, F.; Dan, K.; Inokuchi, K. Importance of c-kit mutation detection method sensitivity in prognostic analyses of t(8;21)(q22;q22) acute myeloid leukemia. Leukemia 2011, 25, 1423-1432.
12. Aki, I. Oligonucleotide for Detection Test of Polymorphism of EGFR exon19 and Use thereof. JP Patent Application Number 2011-103818, 6 May 2011.
13. Matsumoto, N.; Kakihara, F.; Kimura, S.; Kurebayashi, Y.; Hirai, M.; Yohda, M.; Hasegawa, S. Single nucleotide polymorphism genotyping of cyp2c19 using a new automated system. Anal. Biochem. 2007, 370, 121-123.
14. Desta, Z.; Zhao, X.; Shin, J.G.; Flockhart, D.A. Clinical significance of the cytochrome p450 2c19 genetic polymorphism. Clin. Pharmacokinet. 2002, 41, 913-958.
15. Shi, S.; Klotz, U. Proton pump inhibitors: An update of their clinical use and pharmacokinetics. Eur. J. Clin. Pharmacol. 2008, 64, 935-951.
16. Han, J.Y.; Lim, H.S.; Shin, E.S.; Yoo, Y.K.; Park, Y.H.; Lee, J.E.; Jang, I.J.; Lee, D.H.; Lee, J.S. Comprehensive analysis of ugt1a polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J. Thorac. Oncol. 2006, 24, 2237-2244.
17. Ando, Y.; Saka, H.; Ando, M.; Sawa, T.; Muro, K.; Ueoka, H.; Yokoyama, A.; Saitoh, S.; Shimokata, K.; Hasegawa, Y. Polymorphisms of udp-glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis. Cancer Res. 2000, 60, 6921-6926.
18. Ando, Y.; Fujita, K.; Sasaki, Y.; Hasegawa, Y. Ugt1ai*6 and ugt1a1*27 for individualized irinotecan chemotherapy. Curr. Opin. Mol. Ther. 2007, 9, 258-262.
19. Satoh, T.; Ura, T.; Yamada, Y.; Yamazaki, K.; Tsujinaka, T.; Munakata, M.; Nishina, T.; Okamura, S.; Esaki, T.; Sasaki, Y.; et al. Genotype-directed, dose-finding study of irinotecan in cancer patients with ugt1a1*28 and/or ugt1a1*6 polymorphisms. Cancer Sci. 2011, 102, 1868-1873.
20. Taus, A.; Vollmer, I.; Arriola, E. Activating and resistance mutations of the epidermal growth factor receptor (egfr) gene and non-small cell lung cancer: A clinical reality. Arch. Bronconeumol. 2011, 47, 103-105.
21. De Pas, T.; Toffalorio, F.; Manzotti, M.; Fumagalli, C.; Spitaleri, G.; Catania, C.; Delmonte, A.; Giovannini, M.; Spaggiari, L.; de Braud, F.; et al. Activity of epidermal growth factor receptortyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations. J. Thorac. Oncol. 2011, 6, 1895-1901.
22. Gazdar, A.F. Activating and resistance mutations of egfr in non-small-cell lung cancer: Role in clinical response to egfr tyrosine kinase inhibitors. Oncogene 2009, 28, S24-S31.
23. Yang, S.Y.; Yang, T.Y.; Chen, K.C.; Li, Y.J.; Hsu, K.H.; Tsai, C.R.; Chen, C.Y.; Hsu, C.P.; Hsia, J.Y.; Chuang, C.Y.; et al. Egfr l858r mutation and polymorphisms of genes related to estrogen biosynthesis and metabolism in never-smoking female lung adenocarcinoma patients. Clin. Cancer Res. 2011, 17, 2149-2158.
24. Sharma, S.V.; Bell, D.W.; Settleman, J.; Haber, D.A. Epidermal growth factor receptor mutations in lung cancer. Nature Rev. Cancer 2007, 7, 169-181.
25. Riely, G.J.; Pao, W.; Pham, D.; Li, A.R.; Rizvi, N.; Venkatraman, E.S.; Zakowski, M.F.; Kris, M.G.; Ladanyi, M.; Miller, V.A. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin. Cancer Res. 2006, 12, 839-844.
26. Molina-Vila, M.A.; Bertran-Alamillo, J.; Mayo, C.; Rosell, R. Screening for egfr mutations in lung cancer. Discov. Med. 2009, 8, 181-184.
27. Mitsudomi, T.; Morita, S.; Yatabe, Y.; Negoro, S.; Okamoto, I.; Tsurutani, J.; Seto, T.; Satouchi, M.; Tada, H.; Hirashima, T.; et al. Gefitinib versus cisplatin plus docetaxel in patients with nonsmall-cell lung cancer harbouring mutations of the epidermal growth factor receptor (wjtog3405). Lancet. Oncol. 2010, 11, 121-128.
28. Maemondo, M.; Inoue, A.; Kobayashi, K.; Sugawara, S.; Oizumi, S.; Isobe, H.; Gemma, A.; Harada, M.; Yoshizawa, H.; Kinoshita, I.; et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated egfr. The New England J. Med. 2010, 362, 2380-2388.
29. Suda, K.; Onozato, R.; Yatabe, Y.; Mitsudomi, T. Egfr t790m mutation: A double role in lung cancer cell survival? J. Thorac. Oncol. 2009, 4, 1-4.
30. Yun, C.H.; Mengwasser, K.E.; Toms, A.V.; Woo, M.S.; Greulich, H.; Wong, K.K.; Meyerson, M.; Eck, M.J. The t790m mutation in egfr kinase causes drug resistance by increasing the affinity for ATP. Proc. Nat. Acad. Sci. USA 2008, 105, 2070-2075.
31. Nakamura, T.; Sueoka-Aragane, N.; Iwanaga, K.; Sato, A.; Komiya, K.; Abe, T.; Ureshino, N.; Hayashi, S.; Hosomi, T.; Hirai, M.; et al. A noninvasive system for monitoring resistance to epidermal growth factor receptor tyrosine kinase inhibitors with plasma DNA. J. Thorac. Oncol. 2011, 6, 1639-1648.
32. Jiang, Y.; Kimchi, E.T.; Staveley-O'Carroll, K.F.; Cheng, H.; Ajani, J.A. Assessment of k-ras mutation: A step toward personalized medicine for patients with colorectal cancer. Cancer 2009, 115, 3609-3617.
33. Ureshino, N.; Sueoka-Aragane, N.; Nakamura, T.; Sato, A.; Komiya, K.; Iwanaga, K.; Mitsuoka, M.; Takeda, Y.; Hayashi, S.; Sueoka, E.; et al. A fully integrated, automated and rapid detection system for kras mutations. Oncol. Rep. 2011, 26, 609-613.
34. Karapetis, C.S.; Khambata-Ford, S.; Jonker, D.J.; O'Callaghan, C.J.; Tu, D.; Tebbutt, N.C.; Simes, R.J.; Chalchal, H.; Shapiro, J.D.; Robitaille, S.; et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. New Engl. J. Med. 2008, 359, 1757-1765.
35. Benvenuti, S.; Sartore-Bianchi, A.; Di Nicolantonio, F.; Zanon, C.; Moroni, M.; Veronese, S.; Siena, S.; Bardelli, A. Oncogenic activation of the ras/raf signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 2007, 67, 2643-2648.
36. Jiang, Y.; Mackley, H.; Cheng, H.; Ajani, J.A. Use of k-ras as a predictive biomarker for selecting anti-egf receptor/pathway treatment. Biomark. Med. 2010, 4, 535-541.
37. Pratilas, C.A.; Hanrahan, A.J.; Halilovic, E.; Persaud, Y.; Soh, J.; Chitale, D.; Shigematsu, H.; Yamamoto, H.; Sawai, A.; Janakiraman, M.; et al. Genetic predictors of mek dependence in non-small cell lung cancer. Cancer Res. 2008, 68, 9375-9383.
38. Siena, S.; Sartore-Bianchi, A.; Di Nicolantonio, F.; Balfour, J.; Bardelli, A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J. Nat. Cancer. Inst. 2009, 101, 1308-1324.
39. Akagi, K.; Arai, Y. tm analysis method using a quenching probe is a simple and rapid way to simultaneously detect kras and braf mutations. Rinsho Byori (Japan. J. Clin. Pathol.) 2011, 59, 757-762.
40. Tefferi, A. Classification, Diagnosis and Management of Myeloproliferative Disorders in the JAK2V617F Era. Hematology Am. Soc. Hematol. Educ. Program. 2006, 240-245.
41. Li, Z.; Xu, M.; Xing, S.; Ho, W.T.; Ishii, T.; Li, Q.; Fu, X.; Zhao, Z.J. Erlotinib effectively inhibits jak2v617f activity and polycythemia vera cell growth. J. Biol. Chem. 2007, 282, 3428-3432.
42. Tanaka, R.; Kimura, S.; Ashihara, E.; Yoshimura, M.; Takahashi, N.; Wakita, H.; Itoh, K.; Nishiwaki, K.; Suzuki, K.; Nagao, R.; et al. Rapid automated detection of abl kinase domain mutations in imatinib-resistant patients. Cancer Lett. 2011, 312, 228-234.